Skip to Content

BioLine Rx Ltd BLRX

Morningstar Rating
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BLRX is trading at a 47% discount.
Price
ILS 0.33
Fair Value
ILS 1.76
Uncertainty
Extreme
1-Star Price
ILS 1.62
5-Star Price
ILS 8.28
Economic Moat
Zjr
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BLRX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
Day Range
52-Week Range
Bid/Ask
/
Market Cap
Volume/Avg
/

Key Statistics

Price/Earnings (Normalized)
Price/Sales
15.11
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
49

Comparables

Valuation

Metric
BLRX
RYTM
ITCI
Price/Earnings (Normalized)
Price/Book Value
6.7614.6311.36
Price/Sales
15.1131.1314.46
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
BLRX
RYTM
ITCI
Quick Ratio
1.425.274.95
Current Ratio
1.535.585.41
Interest Coverage
−28.21−13.26
Quick Ratio
BLRX
RYTM
ITCI

Profitability

Metric
BLRX
RYTM
ITCI
Return on Assets (Normalized)
−62.91%−46.12%−13.47%
Return on Equity (Normalized)
−154.82%−76.97%−15.88%
Return on Invested Capital (Normalized)
−100.04%−76.40%−17.96%
Return on Assets
BLRX
RYTM
ITCI
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRMjnlbrdfYns$571.0 Bil
VRTX
Vertex Pharmaceuticals IncKqnzbzwdqRrfsgb$107.8 Bil
REGN
Regeneron Pharmaceuticals IncMckzhcbKmybzs$106.1 Bil
MRNA
Moderna IncYvxnkfrtKyts$42.3 Bil
ARGX
argenx SE ADRWrdhdyjFbtyz$23.7 Bil
BNTX
BioNTech SE ADRXtlzdvcjLmsk$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncLhfzlxmjyJkkyr$19.4 Bil
BMRN
Biomarin Pharmaceutical IncRsztqxsCngqbj$16.7 Bil
RPRX
Royalty Pharma PLC Class AFkrdkxdxwKqnfyyr$13.6 Bil
INCY
Incyte CorpMbgfdwgpYbsrhf$12.8 Bil

Sponsor Center